Online ISSN: 2515-8260

Keywords : kidney disease


Efficacy And Safety Of Sodium Glucose Co- Transporter 2 Inhibitors In Type 2 Diabetes Mellitus Patients

Dr. Pushkar Mani, Dr. Anusha Vohra, Dr. Shipra Jain, Dr Chandrabhan, Dr. Ruchi Mathur

European Journal of Molecular & Clinical Medicine, 2023, Volume 10, Issue 1, Pages 3949-3956

Type 2 Diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia. It affects millions of people worldwide and is the fourth leading cause of death in India. One of the most important and effective treatment to achieve glycemic control in diabetic patients are various oral hypoglycemic agents with adequate lifestyle modifications and physical activities. Sodium glucose cotransporter 2 inhibitors are one such emerging oral hypoglycemic agents that achieve the desired goal with some complimentary benefits. This prospective observational study using four different SGLT2 inhibitors amongst 68 patients with Type II diabetes namely Canagliflozin 100 mg, Dapagliflozin 10 mg, Empagliflozin 25 mg, Remogliflozin 100mg has shown promising results in managing glycemic control along with complimentary benefits including weight loss

DYSFUNCTIONAL HDL- A DEVIL IN DISGUISE AS A PREDICTOR OF PROGRESSION OF CHRONIC KIDNEY DISEASE TO PROVIDE AN ALTERNATIVE TO URINARY ALBUMIN CREATININE RATIO [UACR] MEASUREMENT

Dr. Md Rashid Ahsan Lodhi, Dr.Sayantaann Saha, Dr. C. R. Mallikarjuna, Dr. Asif Ayaz

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 1032-1039

cholesterol (HDL-C) are usually decreased. However, enough data assessing this relationship
is scarce in different literature commenting on kidney disease progression in patients having
chronic kidney disease
Aim: The present study was conducted to assess the correlation between the progression of
chronic kidney disease and serum high-density lipoprotein cholesterol levels to provide an
alternative to urinary albumin-creatinine ratio (UACR) measurement.
Methods:The present study assessed the relationship between the progression of chronic
kidney disease and serum high-density lipoprotein cholesterol levels in 542 subjects with
diagnosed chronic kidney disease. The primary and secondary outcomes assessed were a 50%
reduction in the estimated GFR (Glomerular Filtration Rate) from the baseline values or the
onset of end-stage renal disease (ESRD). The secondary outcomes assessed were the
development of end-stage renal disease.